BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27297785)

  • 1. Post authorization safety study comparing quetiapine to risperidone and olanzapine.
    Heintjes EM; Overbeek JA; Penning-van Beest FJ; Brobert G; Herings RM
    Hum Psychopharmacol; 2016 Jul; 31(4):304-12. PubMed ID: 27297785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.
    Layton D; Harris S; Wilton LV; Shakir SA
    J Psychopharmacol; 2005 Sep; 19(5):473-82. PubMed ID: 16166184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.
    Sacchetti E; Valsecchi P; Parrinello G;
    Schizophr Res; 2008 Jan; 98(1-3):55-65. PubMed ID: 17933497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine and quetiapine: comparative cohort study.
    Harrison-Woolrych M; Skegg K; Ashton J; Herbison P; Skegg DC
    Br J Psychiatry; 2011 Aug; 199(2):140-4. PubMed ID: 21653944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: a nationwide register-based cohort study in Denmark.
    Pasternak B; Svanström H; Ranthe MF; Melbye M; Hviid A
    CNS Drugs; 2014 Oct; 28(10):963-73. PubMed ID: 24895158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
    Schillevoort I; de Boer A; Herings RM; Roos RA; Jansen PA; Leufkens HG
    Ann Pharmacother; 2001 Dec; 35(12):1517-22. PubMed ID: 11793611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
    Byerly MJ; Nakonezny PA; Bettcher BM; Carmody T; Fisher R; Rush AJ
    Schizophr Res; 2006 Sep; 86(1-3):244-50. PubMed ID: 16730951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative risk of cerebrovascular adverse events in community-dwelling older adults using risperidone, olanzapine and quetiapine: a multiple propensity score-adjusted retrospective cohort study.
    Chatterjee S; Chen H; Johnson ML; Aparasu RR
    Drugs Aging; 2012 Oct; 29(10):807-17. PubMed ID: 23018582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Movement Disorders in Children and Adolescents Receiving Antipsychotic Pharmacotherapy: A Population-Based Study.
    Biscontri RG; Jha S; Collins DM; Bugden S; Katz LY; Alessi-Severini S
    J Child Adolesc Psychopharmacol; 2017 Dec; 27(10):892-896. PubMed ID: 29091743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.
    Karagianis J; Williams R; Davis L; Procyshyn R; Monga N; Hanley J; Chandrasena R; Thakur A; Dickson R
    Curr Med Res Opin; 2009 Sep; 25(9):2121-32. PubMed ID: 19601707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database.
    Osborn DP; Petersen I; Beckley N; Walters K; Nazareth I; Hayes J
    J Psychopharmacol; 2018 Oct; 32(10):1098-1103. PubMed ID: 29938561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review.
    Ennis ZN; Damkier P
    Basic Clin Pharmacol Toxicol; 2015 Apr; 116(4):315-20. PubMed ID: 25536446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine.
    Osborn D; Marston L; Nazareth I; King MB; Petersen I; Walters K
    Schizophr Res; 2017 May; 183():116-123. PubMed ID: 27884434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of falls and fractures in older adults using atypical antipsychotic agents: a propensity score-adjusted, retrospective cohort study.
    Chatterjee S; Chen H; Johnson ML; Aparasu RR
    Am J Geriatr Pharmacother; 2012 Apr; 10(2):83-94. PubMed ID: 22306198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
    McEvoy JP; Lieberman JA; Perkins DO; Hamer RM; Gu H; Lazarus A; Sweitzer D; Olexy C; Weiden P; Strakowski SD
    Am J Psychiatry; 2007 Jul; 164(7):1050-60. PubMed ID: 17606657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.